Tools
Stock profile

Denali Therapeutics Inc. (DNLI)

DNLI · Latest close $18.40 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$18.40
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
1
vs previous quarter

Denali Therapeutics Inc. (DNLI) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $363.7K sold). Latest close $18.40 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 4, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-363.7K
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Insider trading · 5% holders · Politician trading · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Baker Bros. Advisors — 1 tracked fund hold DNLI. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 4 sales ($363.7K). Insider trading

Often held alongside

No closely related stocks by co-holding for this stock. Browse all stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Baker Bros. Advisors0.48%3,734,336ADDED (+0.1%) Q3 filed Nov 16
Polen Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -30.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

27.2110.842024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding295 of 8,857 filers
Long-only filers among them292
Change vs 2026 Q1+32 net · 285 entered · 253 exited
Shares reported, all filers156,219,035
Reported value, all filers$3.5B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$0
Net income · FY2025$-512.5M
Total assets · FY2025$1.1B
Shares outstanding159,847,403
Market cap (at latest close)$2.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 202615,475,322
Share of shares outstanding9.68%
Days to cover8.07

Shares short at recent settlements — Jul 31, 2026: 17.4M · Aug 14, 2026: 18.0M · Aug 31, 2026: 16.6M · Sep 15, 2026: 17.1M · Sep 30, 2026: 15.5M · Oct 15, 2026: 15.5M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 3 insiders ($363.7K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 4, 2026Chin Peter ScottChief Medical OfficerSell1,654$22.29$36.9KSEC filing
Sep 2, 2026Thornberry NancySell10,824$22.85$247.3KSEC filing
Sep 2, 2026Thornberry NancySell615$23.74$14.6KSEC filing
Sep 1, 2026Schuth Alexander O.COFO and SecretarySell2,768$23.44$64.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 4, 2026BAILLIE GIFFORD & COSC 13G/A11,960,2307.5%Jun 30, 2026SEC filing
Jul 8, 2026T. Rowe Price Investment Management, Inc.SC 13G/A16,178,96310.2%Jun 30, 2026SEC filing
May 15, 2026T. Rowe Price Investment Management, Inc.SC 13G8,519,1925.4%Mar 31, 2026SEC filing
May 6, 2026FMR LLCSC 13G/A6,672,999.324.2%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Nov 5, 2025FMR LLCSC 13G/A8,536,392.345.8%Sep 30, 2025SEC filing
Aug 12, 2025Wellington Management Group LLPSC 13G/A5,664,7333.9%Jun 30, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A10,490,6107.2%Mar 31, 2025SEC filing
Feb 13, 2025Capital Research Global InvestorsSC 13G/A5,477,2113.8%Dec 31, 2024SEC filing
Feb 12, 2025BAILLIE GIFFORD & COSC 13G/A12,313,9318.6%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Government relations

Lobbying: 9 Lobbying Disclosure Act filings named this company as client, 2025–2026; most common issues: Health Issues (8).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

This stock does not currently pass any tracked screen.

Recent 8-K filings

FiledItemsSource
Nov 3, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 6, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 28, 20262.01 Completion of Acquisition or Disposition of Assets · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Stocks A–Z · Track Record: how the signals scored · Practice timing on DNLI

One email a week: the week’s new filings and research. Subscribe free

← DNA  ·  DNN →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.